Moderna公司正通过强化商业团队建设，为其季节性疫苗业务奠定坚实基础。公司最新规划显示，其目标是在2025年实现16亿至20亿美元的营收预期区间。
这一战略部署凸显了该生物技术巨头对疫苗商业化进程的加速推进。随着全球公共卫生体系对呼吸道疫苗需求的持续增长，Moderna正通过优化销售网络、提升市场渗透率等措施，不断增强其在季节性疫苗领域的竞争壁垒。
值得注意的是，此次公布的营收指引较以往更为具体，反映出公司对核心业务增长轨迹的清晰预判。通过将商业团队建设与产品管线发展相结合，Moderna正在构建一个更具韧性的疫苗生态系统。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.